-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Growth in Short Interest
Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Growth in Short Interest
Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) was the target of a significant increase in short interest in the month of December. As of December 30th, there was short interest totalling 1,180,000 shares, an increase of 12.4% from the December 15th total of 1,050,000 shares. Approximately 7.0% of the company's shares are sold short. Based on an average daily volume of 86,700 shares, the short-interest ratio is currently 13.6 days.
Analyst Ratings Changes
Separately, LADENBURG THALM/SH SH lowered their price target on Aadi Bioscience to $47.00 in a research report on Tuesday, November 15th.
Get Aadi Bioscience alerts:Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of AADI. RA Capital Management L.P. raised its stake in Aadi Bioscience by 54.1% during the third quarter. RA Capital Management L.P. now owns 590,218 shares of the company's stock valued at $8,340,000 after buying an additional 207,190 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Aadi Bioscience by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 567,129 shares of the company's stock valued at $8,014,000 after buying an additional 25,085 shares in the last quarter. State Street Corp raised its stake in Aadi Bioscience by 72.0% during the first quarter. State Street Corp now owns 535,578 shares of the company's stock valued at $9,089,000 after buying an additional 224,178 shares in the last quarter. Ikarian Capital LLC raised its stake in Aadi Bioscience by 97.9% during the second quarter. Ikarian Capital LLC now owns 412,343 shares of the company's stock valued at $1,274,000 after buying an additional 203,975 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Aadi Bioscience by 1.6% during the third quarter. Price T Rowe Associates Inc. MD now owns 251,279 shares of the company's stock valued at $3,552,000 after buying an additional 4,041 shares in the last quarter. Institutional investors and hedge funds own 67.09% of the company's stock.
Aadi Bioscience Trading Up 1.8 %
AADI stock opened at $12.80 on Friday. The stock has a 50-day moving average price of $12.89 and a two-hundred day moving average price of $13.05. Aadi Bioscience has a 12-month low of $11.00 and a 12-month high of $21.15. The company has a market cap of $312.26 million, a PE ratio of -4.30 and a beta of 1.26.Aadi Bioscience (NASDAQ:AADI – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. The company had revenue of $4.25 million for the quarter, compared to analysts' expectations of $3.60 million. Aadi Bioscience had a negative return on equity of 44.28% and a negative net margin of 569.57%. Equities analysts forecast that Aadi Bioscience will post -2.86 EPS for the current fiscal year.
Aadi Bioscience Company Profile
(Get Rating)
Aadi Bioscience, Inc operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.
Further Reading
- Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
Aadi Bioscience,Inc.(納斯達克:AADI-GET評級)是空頭股數12月份大幅增長的目標。截至12月30日,空頭股數共有118萬股,比12月15日的105萬股增加了12.4%。該公司約7.0%的股票被賣空。以日均成交量86,700股計算,目前短息比率為13.6天。
分析師評級發生變化
另外,拉登堡THALM/SH SH在11月15日星期二的一份研究報告中將他們對Aadi Bioscience的目標價下調至47.00美元。
到達Aadi生物科學警報:機構資金流入和流出
幾家機構投資者最近調整了對Aadi的持股。Ra Capital Management L.P.在第三季度將其在Aadi Bioscience的持股增加了54.1%。Ra Capital Management L.P.在上個季度又購買了207,190股後,現在擁有590,218股該公司股票,價值8,340,000美元。Point72 Asset Management L.P.在第三季度將其在Aadi Bioscience的持股增加了4.6%。Point72 Asset Management L.P.在上個季度額外購買了25,085股後,現在擁有567,129股該公司股票,價值8,014,000美元。道富集團在第一季度將其在Aadi Bioscience的持股增加了72.0%。道富銀行目前持有555,578股該公司股票,價值9,089,000美元,上一季度又購買了224,178股。第二季度,伊卡裡安資本有限責任公司將其在Aadi Bioscience的持股比例提高了97.9%。伊卡裡安資本有限責任公司現在擁有412,343股該公司的股票,價值1,274,000美元,上個季度又購買了203,975股。最後,Price T Rowe Associates Inc.MD在第三季度將其在Aadi Bioscience的持股增加了1.6%。Price T Rowe Associates Inc.MD現在持有251,279股該公司股票,價值3,552,000美元,上個季度又購買了4,041股。機構投資者和對沖基金持有該公司67.09%的股票。
Aadi Bioscience股價上漲1.8%
Aadi股價上週五開盤報12.80美元。該股的50日移動均線價格為12.89美元,200日移動均線價格為13.05美元。Aadi Bioscience的12個月低點為11.00美元,12個月高位為21.15美元。該公司市值為3.1226億美元,本益比為-4.30,貝塔係數為1.26。Aadi Bioscience(納斯達克:AADI-GET評級)最近一次發佈季度收益數據是在11月9日週三。該公司公佈本季度每股收益(0.68美元),比分析師普遍預期的(0.75美元)高出0.07美元。該公司本季度營收為425萬美元,高於分析師預期的360萬美元。Aadi Bioscience的淨資產回報率為負44.28%,淨利潤率為負569.57%。股票分析師預測,Aadi Bioscience本財年每股收益將達到2.86歐元。
Aadi生物科學公司簡介
(獲取評級)
Aadi Bioscience,Inc.是一家臨床階段的生物製藥公司。它為具有mTOR通路驅動程式改變的基因定義的癌症患者開發精確療法,例如TSC1或TSC2基因改變。該公司由尼爾·德賽於2007年11月創立,總部設在加利福尼亞州洛杉磯。
進一步閱讀
- 免費獲取StockNews.com關於Aadi生物科學的研究報告(AADI)
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車?
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
獲得《Aadi生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aadi Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧